Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open randomized controlled study of the anti-inflammatory properties of Renagel in chronic hemodialysis patients
2005-004052-12Phase 2Active
- Sponsor
- Asociación Científica para la Investigación Nefrológica
- Start
- Mar 2006
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in end-stage kidney disease (ESKD) comparing Renagel arm with Calcium acetate control arm (2 arms). Primary endpoints: Serum pro-inflammatory and anti-inflammatory cytokine concentrations and C-reactive protein. Started Mar 2006; status: active.
02
Drugs
sevelamer carbonatePhoscat
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2005-004052-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004052-12.